These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32735872)

  • 41. Development and characterization of an inducible Dicer conditional knockout mouse model of Parkinson's disease: validation of the antiparkinsonian effects of a sigma-1 receptor agonist and dihydromyricetin.
    Guo CH; Cao T; Zheng LT; Waddington JL; Zhen XC
    Acta Pharmacol Sin; 2020 Apr; 41(4):499-507. PubMed ID: 32112040
    [TBL] [Abstract][Full Text] [Related]  

  • 42. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
    Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.
    Callizot N; Guénet JL; Baillet C; Warter JM; Poindron P
    Neurobiol Dis; 2001 Jun; 8(3):447-58. PubMed ID: 11442353
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pitx3 deficiency produces decreased dopamine signaling and induces motor deficits in Pitx3(-/-) mice.
    Le W; Zhang L; Xie W; Li S; Dani JA
    Neurobiol Aging; 2015 Dec; 36(12):3314-3320. PubMed ID: 26363812
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
    Wakamatsu M; Iwata S; Funakoshi T; Yoshimoto M
    J Neurosci Res; 2008 Feb; 86(3):640-6. PubMed ID: 17896793
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice.
    Mango D; Bonito-Oliva A; Ledonne A; Cappellacci L; Petrelli R; Nisticò R; Berretta N; Fisone G; Mercuri NB
    Exp Neurol; 2014 Nov; 261():733-43. PubMed ID: 25173217
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nigral dopamine loss induces a global upregulation of presynaptic dopamine D1 receptor facilitation of the striatonigral GABAergic output.
    Ding S; Li L; Zhou FM
    J Neurophysiol; 2015 Mar; 113(6):1697-711. PubMed ID: 25552639
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist.
    Eden RJ; Costall B; Domeney AM; Gerrard PA; Harvey CA; Kelly ME; Naylor RJ; Owen DA; Wright A
    Pharmacol Biochem Behav; 1991 Jan; 38(1):147-54. PubMed ID: 1673248
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impaired motor coordination in Pitx3 overexpression mice.
    Kim H; Quan X; Seong Y; Kim J
    Biochem Biophys Res Commun; 2014 Apr; 446(4):1211-8. PubMed ID: 24680684
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
    Yang X; Zhu Z; Ding X; Wang X; Cui G; Hua F; Xiang J
    Brain Res; 2018 May; 1687():66-73. PubMed ID: 29452071
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Endogenous dopaminergic tone and dopamine agonist action.
    Treseder SA; Smith LA; Jenner P
    Mov Disord; 2000 Sep; 15(5):804-12. PubMed ID: 11009183
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A new knock-in mouse model of l-DOPA-responsive dystonia.
    Rose SJ; Yu XY; Heinzer AK; Harrast P; Fan X; Raike RS; Thompson VB; Pare JF; Weinshenker D; Smith Y; Jinnah HA; Hess EJ
    Brain; 2015 Oct; 138(Pt 10):2987-3002. PubMed ID: 26220941
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
    Mantas I; Yang Y; Mannoury-la-Cour C; Millan MJ; Zhang X; Svenningsson P
    Neuropharmacology; 2020 Jan; 162():107829. PubMed ID: 31666199
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased dopamine D2 receptor activity in the striatum alters the firing pattern of dopamine neurons in the ventral tegmental area.
    Krabbe S; Duda J; Schiemann J; Poetschke C; Schneider G; Kandel ER; Liss B; Roeper J; Simpson EH
    Proc Natl Acad Sci U S A; 2015 Mar; 112(12):E1498-506. PubMed ID: 25675529
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice.
    Li L; Qiu G; Ding S; Zhou FM
    Brain Res; 2013 Jan; 1491():236-50. PubMed ID: 23159831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relative contributions of severe dopaminergic neuron ablation and dopamine depletion to cognitive impairment.
    Morgan RG; Gibbs JT; Melief EJ; Postupna NO; Sherfield EE; Wilson A; Keene CD; Montine TJ; Palmiter RD; Darvas M
    Exp Neurol; 2015 Sep; 271():205-14. PubMed ID: 26079646
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dopaminergic D2 receptor is a key player in the substantia nigra pars compacta neuronal activation mediated by REM sleep deprivation.
    Proença MB; Dombrowski PA; Da Cunha C; Fischer L; Ferraz AC; Lima MM
    Neuropharmacology; 2014 Jan; 76 Pt A():118-26. PubMed ID: 24012539
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Keber U; Klietz M; Carlsson T; Oertel WH; Weihe E; Schäfer MK; Höglinger GU; Depboylu C
    Neuroscience; 2015 Jul; 298():302-17. PubMed ID: 25892702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
    Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.